Press release
Natural Killer (NK) Cell Therapies Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Allogene Therapeutics, Kiadis Pharma, Gkycostem Therapeutics, Fate therapeutics, N
"Natural Killer (NK) Cell Therapies Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Natural Killer (NK) Cell Therapies Market.
The Natural Killer (NK) Cell Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Natural Killer (NK) Cell Therapies Pipeline Report: https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Natural Killer (NK) Cell Therapies treatment therapies with a considerable amount of success over the years.
• Natural Killer (NK) Cell Therapies companies working in the treatment market are Century Therapeutics, CytoImmune Therapeutics, Nkarta Therapeutics, Deverra Therapeutic, BrightPath Biotherapeutics, Affimed, Dragonfly Therapeutics, ImmunityBio, Affimed, CytoVac, XNK Therapeutics, Nektar Therapeutics, and others, are developing therapies for the Natural Killer (NK) Cell Therapies treatment
• Emerging Natural Killer (NK) Cell Therapies therapies in the different phases of clinical trials are- CNTY-102, CYTO NK 203, NKX101, DVX-201, BP 2201, AFM24, GTB-3550, DF6002, DF 1001, PD-L1 t-haNK, AFM13, ALECSAT, CellProtect, NKTR-214 (Bempegaldesleuki n), and others are expected to have a significant impact on the Natural Killer (NK) Cell Therapies market in the coming years.
• In January 2024, The initial individual diagnosed with metastatic castration-resistant prostate cancer (mCRPC) has received treatment in the phase 1/2 CaRe PC trial (NCT06056791) investigating INKmune, a biological therapy. INKmune aims to enhance the performance of the patient's natural killer (NK) cells, specifically targeting them. This therapy involves a patented pharmaceutical-grade tumor cell line that does not replicate, connecting with inactive NK cells and providing various crucial activation signals, similar to the effect of at least 3 cytokines used together in treatment. Administration of INKmune is through intravenous (IV) infusion.
• In December 2023, NAYA Biosciences Inc. ("NAYA"), a company that recently finalized a definitive merger agreement with INVO Bioscience to establish an expanded, publicly-traded life science enterprise focused on enhancing patient accessibility to groundbreaking treatments in fertility, oncology, and regenerative medicine, has joined forces with ONK Therapeutics ("ONK"). ONK is an innovative cell therapy firm committed to developing advanced off-the-shelf natural killer (NK) cell therapies. Together, they've announced a collaborative research initiative to assess a combined therapy approach involving NAYA's FLEX-NK™ bispecific antibodies and ONK's meticulously engineered natural killer (NK) cells. Specifically, the collaboration aims to investigate the potential synergy between NAYA's GPC3-targeted NY-303 FLEX-NK™ bispecific antibody and ONK's ONKT105, which comprises CISH + TGFβR2 double knock-out (KO) alongside sIL-15 knock-in (KI) allogeneic NK cell therapy.
Natural Killer (NK) Cell Therapies Overview
Natural killer cells, alternatively referred to as NK cells, belong to the lymphocyte category and are crucial elements of the innate immune system. These cells possess a high level of specificity and act as significant agents in the body's defense against both tumor cells and cells infected by viruses.
Get a Free Sample PDF Report to know more about Natural Killer (NK) Cell Therapies Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Natural Killer (NK) Cell Therapies Drugs Under Different Phases of Clinical Development Include:
• CNTY-102: Century Therapeutics
• CYTO NK 203: CytoImmune Therapeutics
• NKX101: Nkarta Therapeutics
• DVX-201: Deverra Therapeutic
• BP 2201: BrightPath Biotherapeutics
• AFM24: Affimed
• GTB-3550: GT Biopharma
• DF6002: Dragonfly Therapeutics
• DF 1001: Dragonfly Therapeutics
• PD-L1 t-haNK: ImmunityBio
• AFM13: Affimed
• ALECSAT: CytoVac
• CellProtect: XNK Therapeutics
• NKTR-214 (Bempegaldesleuki n): Nektar Therapeutics
Natural Killer (NK) Cell Therapies Route of Administration
Natural Killer (NK) Cell Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intracranial
• Intramuscular
• Intratumoral
• Intravenous
• Intravenous
• Parenteral
• Subcutaneous
• Molecule Type
Natural Killer (NK) Cell Therapies Molecule Type
Natural Killer (NK) Cell Therapies Products have been categorized under various Molecule types, such as
• Small molecule
• Antibodies
• Beta Glucans
• CAR-NK cell therapy
• Cell Therapy
• Gene therapies
• Glycolipid
• NK Cell therapy
• NK T-Cell therapy
• Oligodeoxyribonucleotides
• Proteins
• RNA
• Stem cell therapies
• Vaccines
• Product Type
Natural Killer (NK) Cell Therapies Pipeline Therapeutics Assessment
• Natural Killer (NK) Cell Therapies Assessment by Product Type
• Natural Killer (NK) Cell Therapies By Stage and Product Type
• Natural Killer (NK) Cell Therapies Assessment by Route of Administration
• Natural Killer (NK) Cell Therapies By Stage and Route of Administration
• Natural Killer (NK) Cell Therapies Assessment by Molecule Type
• Natural Killer (NK) Cell Therapies by Stage and Molecule Type
DelveInsight's Natural Killer (NK) Cell Therapies Report covers around 140+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Natural Killer (NK) Cell Therapies product details are provided in the report. Download the Natural Killer (NK) Cell Therapies pipeline report to learn more about the emerging Natural Killer (NK) Cell Therapies therapies at:
https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Natural Killer (NK) Cell Therapies Therapeutics Market include:
Key companies developing therapies for Natural Killer (NK) Cell Therapies are - Allogene Therapeutics, Kiadis Pharma, Gkycostem Therapeutics, Fate therapeutics, Nkarta Therapeutics, Cytovia Therapeutics, and others.
Natural Killer (NK) Cell Therapies Pipeline Analysis:
The Natural Killer (NK) Cell Therapies pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Natural Killer (NK) Cell Therapies with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Natural Killer (NK) Cell Therapies Treatment.
• Natural Killer (NK) Cell Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Natural Killer (NK) Cell Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Natural Killer (NK) Cell Therapies market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Natural Killer (NK) Cell Therapies drugs and therapies-
https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Natural Killer (NK) Cell Therapies Pipeline Market Drivers
• Increasing interest towards NK Cell Therapies among biotech and pharma companies, increase in collaborations and acquisitions between companies, increase in clinical and pre-clinical research with positive results are some of the important factors that are fueling the Natural Killer (NK) Cell Therapies Market.
Natural Killer (NK) Cell Therapies Pipeline Market Barriers
• However, cumbersome preparation method of CAR NK cells, autologous NK cells cannot serve as an effective treatment modality for solid tumors and other factors are creating obstacles in the Natural Killer (NK) Cell Therapies Market growth.
Scope of Natural Killer (NK) Cell Therapies Pipeline Drug Insight
• Coverage: Global
• Key Natural Killer (NK) Cell Therapies Companies: Century Therapeutics, CytoImmune Therapeutics, Nkarta Therapeutics, Deverra Therapeutic, BrightPath Biotherapeutics, Affimed, Dragonfly Therapeutics, ImmunityBio, Affimed, CytoVac, XNK Therapeutics, Nektar Therapeutics, and others
• Key Natural Killer (NK) Cell Therapies Therapies: CNTY-102, CYTO NK 203, NKX101, DVX-201, BP 2201, AFM24, GTB-3550, DF6002, DF 1001, PD-L1 t-haNK, AFM13, ALECSAT, CellProtect, NKTR-214 (Bempegaldesleuki n), and others
• Natural Killer (NK) Cell Therapies Therapeutic Assessment: Natural Killer (NK) Cell Therapies current marketed and Natural Killer (NK) Cell Therapies emerging therapies
• Natural Killer (NK) Cell Therapies Market Dynamics: Natural Killer (NK) Cell Therapies market drivers and Natural Killer (NK) Cell Therapies market barriers
Request for Sample PDF Report for Natural Killer (NK) Cell Therapies Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Natural Killer (NK) Cell Therapies Report Introduction
2. Natural Killer (NK) Cell Therapies Executive Summary
3. Natural Killer (NK) Cell Therapies Overview
4. Natural Killer (NK) Cell Therapies- Analytical Perspective In-depth Commercial Assessment
5. Natural Killer (NK) Cell Therapies Pipeline Therapeutics
6. Natural Killer (NK) Cell Therapies Late Stage Products (Phase II/III)
7. Natural Killer (NK) Cell Therapies Mid Stage Products (Phase II)
8. Natural Killer (NK) Cell Therapies Early Stage Products (Phase I)
9. Natural Killer (NK) Cell Therapies Preclinical Stage Products
10. Natural Killer (NK) Cell Therapies Therapeutics Assessment
11. Natural Killer (NK) Cell Therapies Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Natural Killer (NK) Cell Therapies Key Companies
14. Natural Killer (NK) Cell Therapies Key Products
15. Natural Killer (NK) Cell Therapies Unmet Needs
16 . Natural Killer (NK) Cell Therapies Market Drivers and Barriers
17. Natural Killer (NK) Cell Therapies Future Perspectives and Conclusion
18. Natural Killer (NK) Cell Therapies Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Natural Killer (NK) Cell Therapies Market https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Natural Killer (NK) Cell Therapies Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Latest Reports:
Lung Transplant Rejection Market https://www.delveinsight.com/report-store/lung-transplant-rejection-market
DelveInsight's "Lung Transplant Rejection Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Lung Transplant Rejection, historical and forecasted epidemiology as well as the Lung Transplant Rejection market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.
CAR T-Cell Therapy for Multiple Myeloma Market
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market
DelveInsight's "CAR-T Cell Therapy for Multiple Myeloma Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of multiple myeloma and various CAR-Ts used in multiple myeloma, and CAR-Ts historical and forecasted market trends in multiple myeloma in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Insulin Resistance Market
https://www.delveinsight.com/report-store/insulin-resistance-market
DelveInsight's "Insulin Resistance Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Insulin Resistance, historical and forecasted epidemiology as well as the Insulin Resistance market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Dyskinesia Market
https://www.delveinsight.com/report-store/dyskinesia-market
DelveInsight's "Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dyskinesia, historical and forecasted epidemiology as well as the Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hemophilia Market
https://www.delveinsight.com/report-store/hemophilia-market
DelveInsight's "Hemophilia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Paroxysmal Nocturnal Hemoglobinuria Market
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Paroxysmal Nocturnal Hemoglobinuria historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, the EU4 (Germany, France, Italy, Spain), the UK and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Natural Killer (NK) Cell Therapies Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Allogene Therapeutics, Kiadis Pharma, Gkycostem Therapeutics, Fate therapeutics, N here
News-ID: 3345523 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Cell
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
Cell Banking Outsourcing Market Report 2018: Segmentation by Type of Bank (Maste …
Global Cell Banking Outsourcing market research report provides company profile for Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY…
